UA93488C2 - Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг - Google Patents

Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг

Info

Publication number
UA93488C2
UA93488C2 UAA200705812A UAA200705812A UA93488C2 UA 93488 C2 UA93488 C2 UA 93488C2 UA A200705812 A UAA200705812 A UA A200705812A UA A200705812 A UAA200705812 A UA A200705812A UA 93488 C2 UA93488 C2 UA 93488C2
Authority
UA
Ukraine
Prior art keywords
antibody
glypican
sugar chain
modified sugar
fucose
Prior art date
Application number
UAA200705812A
Other languages
English (en)
Russian (ru)
Inventor
Кійотака Накано
Ізумі Суго
Масаміті Сугімото
Такахіро Ісігуро
Мегумі Танака
Сігеюкі Іідзіма
Original Assignee
Чугаі Сейяку Кабусікі Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугаі Сейяку Кабусікі Кайся filed Critical Чугаі Сейяку Кабусікі Кайся
Publication of UA93488C2 publication Critical patent/UA93488C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Винахід належить до композиції антитіл, які специфічно зв’язують гліпікан-3 (GPC3), частина з яких містить модифікований цукровий ланцюг, де зазначені антитіла або позбавлені фукози, або містять приєднаний дворозсікаючий N-ацетилглюкозамід (GlcNAc). Винахід також належить до способу одержання антитіла до гліпікану -3 за допомогою клітини, яка має зменшену здатність приєднання фукози до цукрових ланцюгів, зокрема з використанням клітини, позбавленої транспортера фукози, а також до протиракового лікарського засобу, який має як активний інгредієнт заявлену композицію антитіл.
UAA200705812A 2004-10-26 2005-10-26 Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг UA93488C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004311356 2004-10-26
PCT/JP2005/020057 WO2006046751A1 (ja) 2004-10-26 2005-10-26 糖鎖改変抗グリピカン３抗体

Publications (1)

Publication Number Publication Date
UA93488C2 true UA93488C2 (uk) 2011-02-25

Family

ID=36227980

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200705812A UA93488C2 (uk) 2004-10-26 2005-10-26 Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг

Country Status (20)

Country Link
US (2) US7867734B2 (uk)
EP (1) EP1816140A4 (uk)
JP (1) JP4794457B2 (uk)
KR (1) KR101296931B1 (uk)
CN (1) CN101068836B (uk)
AU (1) AU2005297772B2 (uk)
BR (1) BRPI0518279A2 (uk)
CA (1) CA2585196C (uk)
CR (1) CR9151A (uk)
HK (1) HK1110335A1 (uk)
IL (1) IL182662A (uk)
MA (1) MA29025B1 (uk)
MX (1) MX2007004593A (uk)
NO (1) NO20072366L (uk)
NZ (1) NZ554940A (uk)
RU (1) RU2451030C2 (uk)
TW (1) TWI468514B (uk)
UA (1) UA93488C2 (uk)
WO (1) WO2006046751A1 (uk)
ZA (1) ZA200703888B (uk)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
DE602004028249D1 (de) * 2003-06-18 2010-09-02 Chugai Pharmaceutical Co Ltd Fucosetransporter
AU2005256113B2 (en) * 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
JP4733042B2 (ja) 2004-08-24 2011-07-27 中外製薬株式会社 抗グリピカン３抗体を用いたアジュバント療法
CN101068836B (zh) * 2004-10-26 2013-08-14 中外制药株式会社 糖链改变的抗磷脂酰肌醇聚糖3抗体
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
PT2178921E (pt) 2007-07-17 2016-03-23 Squibb & Sons Llc Anticorpos monoclonais contra glipicano-3
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
RU2445366C2 (ru) * 2007-09-28 2012-03-20 Чугаи Сейяку Кабусики Кайся Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US8589541B2 (en) 2009-01-28 2013-11-19 Headwater Partners I Llc Device-assisted services for protecting network capacity
US8583781B2 (en) 2009-01-28 2013-11-12 Headwater Partners I Llc Simplified service network architecture
US11985155B2 (en) 2009-01-28 2024-05-14 Headwater Research Llc Communications device with secure data path processing agents
AU2012228100B2 (en) 2011-03-17 2016-09-08 The University Of Birmingham Re-directed immunotherapy
EP4119947A1 (en) 2012-12-21 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
JP2017504329A (ja) * 2014-01-16 2017-02-09 キャリスタ， インコーポレイテッド アミノ酸の増強された産生のための微生物および関連する方法
JP6827319B2 (ja) 2014-05-08 2021-02-10 中外製薬株式会社 Ｇｐｃ３標的治療剤療法が有効である患者に投与されるｇｐｃ３標的治療剤
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2017002934A1 (ja) 2015-07-01 2017-01-05 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
IL257324B (en) * 2015-08-03 2022-08-01 Carsgen Therapeutics Ltd Antibody against glypican-3 and its use
KR101796688B1 (ko) * 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
AU2017212484C1 (en) 2016-01-27 2020-11-05 Medimmune, Llc Methods for preparing antibodies with a defined glycosylation pattern
EP4112641A1 (en) 2016-03-15 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
SG11201900634VA (en) 2016-07-26 2019-02-27 Tessa Therapeutics Pte Ltd Chimeric antigen receptor
JP7125347B2 (ja) 2016-08-22 2022-08-24 中外製薬株式会社 ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
CN106591371A (zh) * 2016-11-25 2017-04-26 哈尔滨百伊生生物科技有限公司 Cd16a/gpc3双抗慢病毒表达载体及其构建方法和应用
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
AU2019354395A1 (en) 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
US11702482B2 (en) 2018-12-17 2023-07-18 Revitope Limited Twin immune cell engager
TW202112812A (zh) * 2019-05-24 2021-04-01 香港商安立璽榮生醫(香港)有限公司 Csf1r抗體、il10融合蛋白及其用途
CN113905757A (zh) 2019-06-05 2022-01-07 中外制药株式会社 抗体切割位点结合分子
CN117062834A (zh) * 2021-02-10 2023-11-14 先声再明医药有限公司 Gpc3人源化抗体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0242355A (ja) 1988-08-02 1990-02-13 Hitachi Constr Mach Co Ltd 超音波検査装置
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04336051A (ja) 1991-05-10 1992-11-24 Toshiba Corp 超音波診断装置
CA2118508A1 (en) * 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
TR199901949T2 (xx) * 1997-02-12 2000-01-21 Chugai Seiyaku Kabushiki Kaisha. Lemfositik t�m�rler i�in �areler.
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
BR9812846A (pt) * 1997-10-03 2000-08-08 Chugai Pharmaceutical Co Ltd Anticorpo humanizado natural
JPH11118775A (ja) 1997-10-09 1999-04-30 Canon Inc 超音波検査装置
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
JP3606132B2 (ja) 1999-10-14 2005-01-05 Ｊｆｅエンジニアリング株式会社 超音波探傷方法およびその装置
JP2002048867A (ja) 2000-08-07 2002-02-15 Mitsubishi Heavy Ind Ltd 音響探査装置
US6825273B2 (en) 2000-09-12 2004-11-30 Union Carbide Chemicals & Plastics Technology Corporation Polymer composites containing alkylene oxide copolymers
CA2785941C (en) * 2000-10-06 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
JP4336051B2 (ja) 2001-01-31 2009-09-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信端末、発呼制限方法及びプログラム
CA2442801A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
EP1780273B1 (en) * 2001-06-22 2010-10-06 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican 3 antibody
NZ603111A (en) * 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
JP3961359B2 (ja) 2002-07-18 2007-08-22 株式会社東芝 超音波画像化装置
JP4087098B2 (ja) 2001-11-14 2008-05-14 株式会社東芝 超音波検査装置
KR100559808B1 (ko) 2001-11-14 2006-03-15 가부시끼가이샤 도시바 검사 장치 및 초음파 검사 장치
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
EP1506406B1 (en) 2002-05-23 2009-03-11 Sunnybrook and Women's College Health Sciences Centre Diagnosis of hepatocellular carcinoma
AU2003254950A1 (en) 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JPWO2005023301A1 (ja) * 2003-09-04 2006-11-02 中外製薬株式会社 胆管癌治療剤および検出薬
ITBO20040008U1 (it) 2004-02-03 2004-05-03 Tonazzi S R L Macchina per il riempimento e la chiusura di tubetti
AU2005256113B2 (en) * 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
RU2404763C2 (ru) * 2004-08-08 2010-11-27 Элиаху ХАЙАТ Фармацевтическая композиция для снижения избыточных уровней сахара в крови больных сахарным диабетом
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
JP4733042B2 (ja) 2004-08-24 2011-07-27 中外製薬株式会社 抗グリピカン３抗体を用いたアジュバント療法
CN101068836B (zh) 2004-10-26 2013-08-14 中外制药株式会社 糖链改变的抗磷脂酰肌醇聚糖3抗体
EP1829961A4 (en) * 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
RU2510400C9 (ru) * 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
CN102027372A (zh) * 2008-03-17 2011-04-20 国立大学法人宫崎大学 使用抗磷脂酰肌醇蛋白聚糖3抗体的肝癌细胞的检测法
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.

Also Published As

Publication number Publication date
EP1816140A4 (en) 2009-09-02
ZA200703888B (en) 2009-11-25
CA2585196C (en) 2015-01-06
WO2006046751A1 (ja) 2006-05-04
JPWO2006046751A1 (ja) 2008-05-22
NZ554940A (en) 2010-04-30
EP1816140A1 (en) 2007-08-08
AU2005297772A1 (en) 2006-05-04
US20080124330A1 (en) 2008-05-29
NO20072366L (no) 2007-06-21
IL182662A0 (en) 2007-09-20
TWI468514B (zh) 2015-01-11
KR20070070222A (ko) 2007-07-03
US7867734B2 (en) 2011-01-11
KR101296931B1 (ko) 2013-08-14
TW200621980A (en) 2006-07-01
BRPI0518279A2 (pt) 2008-11-11
CN101068836A (zh) 2007-11-07
RU2007119579A (ru) 2008-12-10
JP4794457B2 (ja) 2011-10-19
MA29025B1 (fr) 2007-11-01
MX2007004593A (es) 2007-06-22
CN101068836B (zh) 2013-08-14
RU2451030C2 (ru) 2012-05-20
HK1110335A1 (en) 2008-07-11
IL182662A (en) 2014-09-30
US20110033452A1 (en) 2011-02-10
CR9151A (es) 2008-03-18
CA2585196A1 (en) 2006-05-04
AU2005297772B2 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
UA93488C2 (uk) Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг
TW200833712A (en) Antibodies against insulin-like growth factor I receptor and uses thereof
WO2007095506A8 (en) Oligosaccharide modification and labeling of proteins
MX2010007443A (es) Metodo para tratar anemias de respuesta baja a eritropoyetina.
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
EA200800269A1 (ru) Пищевые изделия со средствами доставки и способы их получения
WO2003008431A1 (fr) Methode de production d'un derive d'asparagine de chaines des sucres
UA95284C2 (uk) Антитіла до рецептора інсулінподібного фактора росту i та їх застосування
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
EA200401325A1 (ru) Клетки с модифицированным геномом
TW200745103A (en) Substituted 7-azaindazoles, compositions containing them, production process and use
EP2368913A3 (en) Glyco-engineered antibodies
DK1898721T3 (da) Fremgangsmåde til fremstilling af en vandig suspension og et pulverformigt præparat af et eller flere carotioider
WO2006114308A3 (de) Carrier zum targeting von nervenzellen
CY1106902T1 (el) Κρυσταλλικη μορφη μηλεϊνικης ασεναπινης
IL172938A (en) Antibiotic Antibody-3 Antibodies, Cell Growth Inhibitors, and Pharmaceuticals Containing and Using Them
WO2007028154A3 (en) Encapsulated arsenic drugs
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO2010006173A3 (en) Mineral amino acid polysaccharide complex
WO2007028041A3 (en) Loading of cells with antigens by electroporation
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate
NZ590089A (en) Conjugated vi saccharides
WO2008030564A3 (en) Aglycosylated antibodies and methods of making and using those antibodies
WO2007066192A3 (en) Method for weight reduction
GB0218817D0 (en) Pharmaceutical compounds